CMMB
Price
$3.09
Change
+$0.04 (+1.31%)
Updated
Sep 5 closing price
Capitalization
16.04M
62 days until earnings call
MDGL
Price
$432.89
Change
+$1.68 (+0.39%)
Updated
Sep 5 closing price
Capitalization
9.65B
54 days until earnings call
Interact to see
Advertisement

CMMB vs MDGL

Header iconCMMB vs MDGL Comparison
Open Charts CMMB vs MDGLBanner chart's image
Chemomab Therapeutics
Price$3.09
Change+$0.04 (+1.31%)
Volume$125.21K
Capitalization16.04M
Madrigal Pharmaceuticals
Price$432.89
Change+$1.68 (+0.39%)
Volume$281.2K
Capitalization9.65B
CMMB vs MDGL Comparison Chart in %
Loading...
CMMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CMMB vs. MDGL commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMMB is a Hold and MDGL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (CMMB: $3.09 vs. MDGL: $432.89)
Brand notoriety: CMMB and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CMMB: 151% vs. MDGL: 70%
Market capitalization -- CMMB: $16.04M vs. MDGL: $9.65B
CMMB [@Biotechnology] is valued at $16.04M. MDGL’s [@Biotechnology] market capitalization is $9.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CMMB’s FA Score shows that 1 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • CMMB’s FA Score: 1 green, 4 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than CMMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CMMB’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 3 bullish TA indicator(s).

  • CMMB’s TA Score: 4 bullish, 2 bearish.
  • MDGL’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, CMMB is a better buy in the short-term than MDGL.

Price Growth

CMMB (@Biotechnology) experienced а -1.59% price change this week, while MDGL (@Biotechnology) price change was -1.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

CMMB is expected to report earnings on Nov 07, 2025.

MDGL is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($9.65B) has a higher market cap than CMMB($16M). MDGL YTD gains are higher at: 40.289 vs. CMMB (-57.320). CMMB has higher annual earnings (EBITDA): -12.61M vs. MDGL (-266.74M). CMMB has less debt than MDGL: CMMB (292K) vs MDGL (124M). MDGL has higher revenues than CMMB: MDGL (516M) vs CMMB (0).
CMMBMDGLCMMB / MDGL
Capitalization16M9.65B0%
EBITDA-12.61M-266.74M5%
Gain YTD-57.32040.289-142%
P/E RatioN/AN/A-
Revenue0516M-
Total CashN/A797M-
Total Debt292K124M0%
FUNDAMENTALS RATINGS
CMMB vs MDGL: Fundamental Ratings
CMMB
MDGL
OUTLOOK RATING
1..100
5620
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
67
Overvalued
PROFIT vs RISK RATING
1..100
10027
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
9437
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CMMB's Valuation (21) in the Biotechnology industry is somewhat better than the same rating for MDGL (67) in the Pharmaceuticals Other industry. This means that CMMB’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (27) in the Pharmaceuticals Other industry is significantly better than the same rating for CMMB (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than CMMB’s over the last 12 months.

MDGL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as CMMB (99) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CMMB’s over the last 12 months.

MDGL's Price Growth Rating (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for CMMB (94) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than CMMB’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as CMMB (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CMMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CMMBMDGL
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 9 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
CMMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CGFEX83.010.20
+0.24%
American Funds Growth Fund of Amer 529E
JOEAX13.90N/A
N/A
JOHCM Emerging Markets Opps Investor
DRESX25.19N/A
N/A
Driehaus Emerging Markets Small Cap Gr
GFCUX24.30N/A
N/A
Goldman Sachs Enhanced U.S. Equity R6
LAMSX24.83N/A
N/A
Lord Abbett Dividend Growth R4

CMMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CMMB has been loosely correlated with AXON. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CMMB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMMB
1D Price
Change %
CMMB100%
+1.31%
AXON - CMMB
37%
Loosely correlated
-0.24%
OVID - CMMB
35%
Loosely correlated
-4.65%
HURA - CMMB
30%
Poorly correlated
+0.79%
MDGL - CMMB
29%
Poorly correlated
+0.39%
ORKA - CMMB
29%
Poorly correlated
+9.22%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+0.39%
ALXO - MDGL
56%
Loosely correlated
+12.96%
NAGE - MDGL
45%
Loosely correlated
+0.97%
IPHA - MDGL
44%
Loosely correlated
-2.20%
RNAC - MDGL
43%
Loosely correlated
+6.40%
GHRS - MDGL
43%
Loosely correlated
+0.28%
More